Development of attenuated bovine herpesvirus-4 as a safe, inexpensive, single dose vaccine to control Streptococcus suis infection in domestic pigs

开发减毒牛疱疹病毒 4 作为一种安全、廉价、单剂量疫苗来控制家猪的猪链球菌感染

• 批准号: 104985
• 金额: $ 88.91万
• 依托单位: THE VACCINE GROUP LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104985
• 关键词: Development; attenuated; bovine; herpesvirus; safe

Vaccines are one of medicine's greatest triumphs, having led to the virtual eradication of several deadlybacterial diseases. However, most vaccines in use today were developed by techniques pioneered over 100years ago and do not represent the full potential of the field. Bovine herpes virus vaccines (BoHV-4) are one ofthe most promising classes of new vaccines, combining durability of immunity with low costs of manufacture.In this project, we will develop a novel BoHV-4 vaccine against S. suis - a major disease affecting pig farmersworldwide and a dangerous zoonotic pathogen in humans. The applicants will develop the novel vaccine usingimmunogenic S. suis proteins and then test it in pigs to convincingly demonstrate both efficacy and aquantifiable reduction in antibiotic usage. Our objectives are firstly to commercialize the vaccine within 3 yearspost-project and secondly establish it as a flagship product within our powerful BoHV-4 platform which can betargeted at many other serious bacterial infections affecting both animal and human health. The project isinnovative in that there are currently no effective vaccines for the treatment and prevention of S. suis in pigs

疫苗是医学上最伟大的成就之一，它几乎消除了几种致命的细菌性疾病。然而，当今使用的大多数疫苗都是采用 100 多年前开创的技术开发的，并不能代表该领域的全部潜力。牛疱疹病毒疫苗 (BoHV-4) 是最有前途的新型疫苗之一，兼具免疫力的持久性和低成本的制造优势。在这个项目中，我们将开发一种针对猪链球菌的新型 BoHV-4 疫苗，猪链球菌是一种影响全球养猪户的主要疾病，也是人类危险的人畜共患病原体。申请人将使用免疫原性猪链球菌蛋白开发新型疫苗，然后在猪身上进行测试，以令人信服地证明其功效和可量化的抗生素使用减少量。我们的目标首先是在项目完成后 3 年内将疫苗商业化，其次将其打造为我们强大的 BoHV-4 平台中的旗舰产品，可针对影响动物和人类健康的许多其他严重细菌感染。该项目的创新之处在于目前尚无治疗和预防猪猪链球菌病的有效疫苗